User:WEKX/sandbox
test page
Clinical data | |
---|---|
Pronunciation | acetylsalicylic acid /əˌsiːtəlˌsæl[invalid input: 'ɨ']ˈsɪl[invalid input: 'ɨ']k/ |
Other names | 2-acetoxybenzoic acid acetylsalicylate acetylsalicylic acid O-acetylsalicylic acid |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682878 |
License data | |
Pregnancy category |
|
Routes of administration | Most commonly oral, also rectal, lysine acetylsalicylate may be given intravenously or intramuscularly |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 80–100%[1] |
Protein binding | 80–90%[2] |
Metabolism | Hepatic, (CYP2C19 and possibly CYP3A), some is also hydrolysed to salicylate in the gut wall.[2] |
Elimination half-life | Dose-dependent; 2–3 hours for low doses, 15–30 hours for large doses.[2] |
Excretion | Urine (80–100%), sweat, saliva, feces[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C9H8O4 |
Molar mass | 180.157 g/mol g·mol−1 |
3D model (JSmol) | |
Density | 1.40 g/cm3 |
Melting point | 135 °C (275 °F) |
Boiling point | 140 °C (284 °F) (decomposes) |
Solubility in water | 3 mg/mL (20 °C) |
| |
| |
(verify) |
Aspirin, also known as acetylsalicylic acid (ASA), is a medication, often used to treat pain, fever, and inflammation.[2] Aspirin is also used long-term, at low doses, to help prevent heart attacks, strokes, and blood clot formation in people at high risk of developing blood clots.[3] Low doses of aspirin may be given immediately after a heart attack to prevent clotting and reduce the risk of another heart attack or the death of heart tissue.[4][5] Aspirin may be effective at preventing certain types of cancer, particularly colorectal cancer.[6][7][8]
The main side effects of aspirin are gastric ulcers, stomach bleeding[3], and ringing in the ears, especially with higher doses. While daily aspirin can help prevent a clot-related stroke, it may increase risk of a bleeding stroke (hemorrhagic stroke).[9] In children and adolescents, aspirin is not recommended for flu-like symptoms or viral illnesses, because of the risk of Reye's syndrome.[10]
Medical use
[edit]Aspirin is used in the treatment of a number of conditions, including fever, pain, rheumatic fever, and inflammatory diseases, such as rheumatoid arthritis, pericarditis, and Kawasaki disease.[11] Lower doses of aspirin have also shown to reduce the risk of death from a heart attack, or the risk of stroke in some circumstances.[12][13][14] There is some evidence that aspirin is effective at preventing colorectal cancer, though the mechanisms of this effect are unclear.[15] In the United States low dose aspirin is deemed reasonable in those between 50 and 70 years old who have a more than 10% risk of cardiovascular disease and are not at an increased risk of bleeding who are otherwise healthy.[16]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Not applicable (IV only) |
Protein binding | 94 to 98% |
Metabolism | Hepatic (mostly CYP3A4-mediated) |
Elimination half-life | 180 hours (mean) |
Excretion | Mostly fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C39H43N3O11S |
Molar mass | 761.84 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Clinical data | |
---|---|
License data |
- ^ a b "Zorprin, Bayer Buffered Aspirin (aspirin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 3 April 2014.
- ^ a b c d Brayfield, A, ed. (14 January 2014). "Aspirin". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 3 April 2014.
- ^ a b Lewis, HD; Davis, JW; Archibald, DG; Steinke, WE; Smitherman, TC; Doherty Je, JE; Schnaper, HW; Lewinter, MM; Linares, E; Pouget, JM; Sabharwal, SC; Chesler, E; Demots, H (1983). "Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina". New England Journal of Medicine. 309 (7): 396–403. doi:10.1056/NEJM198308183090703. PMID 6135989.
- ^ Julian, D G; D A Chamberlain; S J Pocock (24 September 1996). "A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial". BMJ. 313 (7070). British Medical Journal: 1429–1431. doi:10.1136/bmj.313.7070.1429. PMC 2353012. PMID 8973228.
- ^ Krumholz, HM; Radford, MJ; Ellerbeck, EF; Hennen, J; Meehan, TP; Petrillo, M; Wang, Y; Kresowik, TF; Jencks, SF (1995). "Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes". Circulation. 92 (10): 2841–2847. doi:10.1161/01.CIR.92.10.2841. PMID 7586250.
- ^ Algra, Annemijn M; Rothwell, Peter M (2012). "Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials". The Lancet Oncology. 13 (5): 518–27. doi:10.1016/S1470-2045(12)70112-2. PMID 22440112.
- ^ Rothwell, Peter M; Price, Jacqueline F; Fowkes, F Gerald R; Zanchetti, Alberto; Roncaglioni, Maria Carla; Tognoni, Gianni; Lee, Robert; Belch, Jill FF; Wilson, Michelle; Mehta, Ziyah; Meade, Tom W (2012). "Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials". The Lancet. 379 (9826): 1602–1612. doi:10.1016/S0140-6736(11)61720-0. PMID 22440946. S2CID 205964516.
{{cite journal}}
: Unknown parameter|displayauthors=
ignored (|display-authors=
suggested) (help) - ^ Rothwell, Peter M; Wilson, Michelle; Price, Jacqueline F; Belch, Jill FF; Meade, Tom W; Mehta, Ziyah (2012). "Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials". The Lancet. 379 (9826): 1591–1601. doi:10.1016/S0140-6736(12)60209-8. PMID 22440947. S2CID 13943035.
- ^ "Daily aspirin therapy: Understand the benefits and risks". MayoClinic.org. Mayo Clinic. Retrieved 21 March 2015.
- ^ Macdonald S (2002). "Aspirin use to be banned in under 16-year olds". BMJ. 325 (7371): 988c–988. doi:10.1136/bmj.325.7371.988/c. PMC 1169585. PMID 12411346.
- ^ "Aspirin". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
- ^ "Aspirin for reducing your risk of heart attack and stroke: know the facts". U.S. Food and Drug Administration. Retrieved 26 July 2012.
- ^ "Aspirin for the prevention of cardiovascular disease". U.S. Preventive Services Task Force. Retrieved 26 July 2012.
- ^ Seshasai, SR; Wijesuriya, S; Sivakumaran, R; Nethercott, S; Erqou, S; Sattar, N; Ray, KK (13 February 2012). "Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials". Archives of Internal Medicine. 172 (3): 209–16. doi:10.1001/archinternmed.2011.628. PMID 22231610.
- ^ Algra, AM; Rothwell, PM (May 2012). "Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials". The Lancet Oncology. 13 (5): 518–27. doi:10.1016/S1470-2045(12)70112-2. PMID 22440112.
- ^ Bibbins-Domingo, K; U.S. Preventive Services Task, Force (21 June 2016). "Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement". Annals of Internal Medicine. 164 (12): 836–45. doi:10.7326/M16-0577. PMID 27064677.